GlassScriptPhysician profile
Stephen N Adler
NPI 1346349404
$4,452.78
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,739 · 2020: $1,505 · 2021: $32.36 · 2022: $36.95 · 2023: $111 · 2024: $28.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $139.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $743.80 | 2019-2020 | |
| Glaxosmithkline, LLC. | $643.06 | 2019-2021 | |
| Genentech USA, INC. | $396.89 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $350.91 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $299.44 | 2019-2020 | |
| Allergan, INC. | $234.11 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $183.32 | 2019-2020 | |
| Abbvie INC. | $176.40 | 2022-2024 | Avycaz |
| Merck Sharp & Dohme LLC | $152.42 | 2019-2020 | |
| Insmed, INC. | $143.73 | 2019-2020 | |
| Genzyme Corporation | $136.87 | 2019-2020 | |
| Pfizer INC. | $106.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $103.14 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $95.45 | 2019-2020 | |
| Shire North American Group INC | $83.59 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $78.24 | 2019-2020 | |
| Circassia INC. | $69.75 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $63.15 | 2019-2020 | |
| Mylan Specialty L.P. | $52.67 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $47.76 | 2019-2020 | |
| Advanced Respiratory, INC | $35.37 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.79 | 2020 | |
| Arbor Pharmaceuticals, INC. | $32.89 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $30.00 | 2019 | |
| Portola Pharmaceuticals, LLC | $25.09 | 2019 | |
| Philips North America LLC | $21.89 | 2019 | |
| United Therapeutics Corporation | $19.32 | 2019-2021 | |
| Pulmonx Corporation | $18.06 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $16.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.33 | 2020 | |
| Vyera Pharmaceuticals, LLC | $14.91 | 2019 | |
| Electromed, INC. | $13.31 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Adler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.